Cue Biopharma vs vTv Therapeutics
CUE and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CUE and VTVT compare
Cue Biopharma is the larger company, worth 1.6 times as much as vTv Therapeutics ($136M against $84.9M).
vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 354% for Cue Biopharma).
vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −20.8% compared with −436% at Cue Biopharma.
vTv Therapeutics scores higher on the StockData Score (11 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CUE | VTVT |
|---|---|---|
| Size and price | ||
| Market cap | $136M | $84.9M |
| Share price | $18.66 | $21.47 |
| Change, 1 year | −8.7% | −23.3% |
| Change, 5 years | −95.8% | −62.2% |
| Beta (5Y) | 2.37 | 1.09 |
| Employees | 29 | 26 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× | 2.3× (better) |
| P/B | 58.7× | 1.2× (better) |
| FCF yield | −37.0% | – |
| Fair value | – | $42.54 |
| Margin of safety | – | 49.5% |
| Growth | ||
| Revenue growth (TTM) | 354% | 216600% (better) |
| Revenue growth, 5Y average | 54.2% | – |
| Profitability | ||
| Operating margin | −262% | −29.8% (better) |
| Net margin | −436% | −20.8% (better) |
| FCF margin | −133% | – |
| Return on equity | −1603% | −11.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.25 | 11.19 (better) |
| Altman Z-score | −30.32 | 0.98 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.6% | 40.6% |
| Held by insiders | 17.4% | 26.3% |
| Insider net buying, 12 months | −$2.3M | – |
| Short interest, % of float | 14.4% | 5.0% |
Go deeper
- CUE stock overview
- CUE income statement
- CUE valuation and score
- VTVT stock overview
- VTVT income statement
- VTVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.